New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Vulvovaginal candidiasis Antifungal therapy Caspofungin Vaginal mucosal delivery Mucoadhesive hydrogel Thermoreversible hydrogel
Fecha
2021-12-12Referencia bibliográfica
Pérez-González, N... [et al.]. New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis. Gels 2021, 7, 259. [https://doi.org/10.3390/gels7040259]
Patrocinador
Spanish National Research Council (CSIC), project no. 202080E231; Agreement with the University of Barcelona and the University of GranadaResumen
Vulvovaginal candidiasis (VVC) poses a significant problem worldwide affecting women
from all strata of society. It is manifested as changes in vaginal discharge, irritation, itching and
stinging sensation. Although most patients respond to topical treatment, there is still a need for
increase the therapeutic arsenal due to resistances to anti-infective agents. The present study was
designed to develop and characterize three hydrogels of chitosan (CTS), Poloxamer 407 (P407)
and a combination of both containing 2% caspofungin (CSP) for the vaginal treatment of VVC.
CTS was used by its mucoadhesive properties and P407 was used to exploit potential advantages
related to increasing drug concentration in order to provide a local effect. The formulations were
physically, mechanically and morphologically characterized. Drug release profile and ex vivo vaginal
permeation studies were performed. Antifungal efficacy against different strains of Candida spp. was
also evaluated. In addition, tolerance of formulations was studied by histological analysis. Results
confirmed that CSP hydrogels could be proposed as promising candidates for the treatment of VVC.